深圳正能量修猫咪2018-03-15 21:43
$Bellicum制药(BLCM)$ 引用“日前,位于休斯顿的癌症免疫疗法新锐Bellicum Pharmaceuticals宣布,其创新细胞疗法BPX-501在治疗罹患急性骨髓性白血病(AML)和原发性免疫缺陷(PID)的儿童患者中,取得了持久的可喜效果。”查看全文
$Bellicum制药(BLCM)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-23-120984 Act: 34 Size: 219 KB 网页链接
$Bellicum制药(BLCM)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-23-056578 Size: 22 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001628280-23-039830 Act: 34 Size: 808 KB 网页链接
$Bellicum制药(BLCM)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-23-038953 Act: 34 Size: 4 MB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001628280-23-033257 Act: 34 Size: 199 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, item 7.01 Accession Number: 0001628280-23-030016 Act: 34 Size: 186 KB 网页链接
$Bellicum制药(BLCM)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-23-028893 Act: 34 Size: 4 MB 网页链接
$Bellicum制药(BLCM)$ 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Accession Number: 0001354457-23-000485 Act: 34 Size: 3 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, item 5.02 Accession Number: 0001628280-23-020619 Act: 34 Size: 197 KB 网页链接
$Bellicum制药(BLCM)$ 8-K Current report, item 3.01 Accession Number: 0001628280-23-020109 Act: 34 Size: 198 KB 网页链接